BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Takayanagi D, Cho H, Machida E, Kawamura A, Takashima A, Wada S, Tsunoda T, Kohno T, Shiraishi K. Update on Epidemiology, Diagnosis, and Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms. Cancers (Basel) 2022;14:1119. [PMID: 35267427 DOI: 10.3390/cancers14051119] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Ramesh A, Chatterjee A, Subramaniam RM. Neuroendocrine Neoplasms: Epidemiology, Diagnosis, and Management. PET Clin 2023:S1556-8598(22)00076-1. [PMID: 36707369 DOI: 10.1016/j.cpet.2022.10.002] [Reference Citation Analysis]
2 Loosen SH, Kostev K, Eschrich J, Krieg S, Krieg A, Luedde T, Jann H, Roderburg C. Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy. Medicine (Baltimore) 2022;101:e32044. [PMID: 36550801 DOI: 10.1097/MD.0000000000032044] [Reference Citation Analysis]
3 Islam MM, Poly TN, Walther BA, Yeh CY, Seyed-Abdul S, Li YJ, Lin MC. Deep Learning for the Diagnosis of Esophageal Cancer in Endoscopic Images: A Systematic Review and Meta-Analysis. Cancers (Basel) 2022;14. [PMID: 36497480 DOI: 10.3390/cancers14235996] [Reference Citation Analysis]
4 Lysanyuk MV, Romashchenko PN, Maistrenko NA. Modern opportunities and problematic aspects of diagnostics and treatment of patients with neuroendocrine tumors. Perm Medical Journal 2022;39:58-68. [DOI: 10.17816/pmj39558-68] [Reference Citation Analysis]
5 Smolkova B, Kataki A, Earl J, Ruz-caracuel I, Cihova M, Urbanova M, Buocikova V, Tamargo S, Rovite V, Niedra H, Schrader J, Kohl Y. Liquid biopsy and preclinical tools for advancing diagnosis and treatment of patients with pancreatic neuroendocrine neoplasms. Critical Reviews in Oncology/Hematology 2022. [DOI: 10.1016/j.critrevonc.2022.103865] [Reference Citation Analysis]
6 Pavlidis ET, Pavlidis TE. Molecular factors, diagnosis and management of gastrointestinal tract neuroendocrine tumors: An update. World J Clin Cases 2022; 10(27): 9573-9587 [DOI: 10.12998/wjcc.v10.i27.9573] [Reference Citation Analysis]
7 Lopes S, Alves M, Rodrigues P. Vasoactive Intestinal Peptide Tumor as the Cause of Persistent Diarrhea: A Diagnostic Challenge. Cureus 2022. [DOI: 10.7759/cureus.29130] [Reference Citation Analysis]
8 Sandra I, Cazacu IM, Croitoru VM, Mihaila M, Herlea V, Diculescu MM, Dima SO, Croitoru AE. Circulating Angiogenic Markers in Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review. CIMB 2022;44:4001-4014. [DOI: 10.3390/cimb44090274] [Reference Citation Analysis]
9 Imperiale A. Neuroendocrine Tumors: Treatment and Management. Cancers (Basel) 2022;14:4048. [PMID: 36011040 DOI: 10.3390/cancers14164048] [Reference Citation Analysis]
10 Djokic M, Hadzialjevic B, Rankovic B, Dezman R, Tomazic A. Neuroendocrine Tumor Arising within Mature Cystic Teratoma of the Pancreas: Literature Review and Case Report. Current Oncology 2022;29:4717-4724. [DOI: 10.3390/curroncol29070374] [Reference Citation Analysis]
11 Kaliszewski K, Ludwig M, Greniuk M, Mikuła A, Zagórski K, Rudnicki J. Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Cancers (Basel) 2022;14:2028. [PMID: 35454934 DOI: 10.3390/cancers14082028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]